Laboratorios Farmaceuticos Rovi (41L) Stock Statistics & Valuation Metrics

Laboratorios Farmaceuticos Rovi has a market cap or net worth of EUR 3.16B. The enterprise value is EUR 2.95B.

Market Cap

EUR 3.16B

Enterprise Value

EUR 2.95B

Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

51,235,764

Owned by Insiders

―

Owned by Institutions

5.28%

Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 16.52%.

Return on Equity (ROE)

0.21

Return on Assets (ROA)

0.15

Return on Invested Capital (ROIC)

16.52%

Return on Capital Employed (ROCE)

0.22

Revenue Per Employee

301.01K

Profits Per Employee

56.86K

Employee Count

2,470

Asset Turnover

0.78

Inventory Turnover

1.01

The current PE Ratio of Laboratorios Farmaceuticos Rovi is 17.28. Laboratorios Farmaceuticos Rovi’s PEG ratio is -2.58.

PE Ratio

17.28

PS Ratio

4.14

PB Ratio

4.57

Price to FCF

18.10

Price to Operating Cash Flow

12.66

PEG Ratio

-2.58

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 743.48M and earned 140.44M in profits. Earnings per share was 2.75.

Revenue

743.48M

Gross Profit

451.65M

Operating Income

173.14M

Pretax Income

183.26M

Net Income

140.44M

EBITDA

203.52M

Earnings Per Share (EPS)

2.75

In the last 12 months, operating cash flow was 252.69M and capital expenditures -75.91M, giving a free cash flow of 176.78M billion.

Operating Cash Flow

252.69M

Free Cash Flow

176.78M

Free Cash Flow per Share

3.46

Laboratorios Farmaceuticos Rovi pays an annual dividend of ―, resulting in a dividend yield of 1.25%

Dividend Per Share

―

Dividend Yield

1.25%

Payout Ratio

N/A

Free Cash Flow Yield

5.53%

Earnings Yield

5.79%

Beta

0.52

52-Week Price Change

-1.11%

50-Day Moving Average

59.12

200-Day Moving Average

65.50

Relative Strength Index (RSI)

68.94

Average Volume (3m)

78

Laboratorios Farmaceuticos Rovi upcoming earnings date is Nov 05, 2026, Before Open (Not Confirmed).

Last Earnings Date

Jul 23, 2026

Next Earnings Date

Nov 05, 2026

Ex-Dividend Date

―

Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 18.32%

Current Ratio

3.14

Quick Ratio

1.55

Debt to Market Cap

0.03

Net Debt to EBITDA

0.12

Interest Coverage Ratio

60.84

In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 42.90M in taxes.

Income Tax

42.90M

Effective Tax Rate

0.23

Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 11.95, with an EV/FCF ratio of 17.99.

EV to Sales

4.11

EV to EBITDA

11.95

EV to Free Cash Flow

17.99

EV to Operating Cash Flow

12.58

Laboratorios Farmaceuticos Rovi has EUR 128.07M in cash and marketable securities with EUR 107.69M in debt, giving a net cash position of EUR 20.38M billion.

Cash & Marketable Securities

EUR 128.07M

Total Debt

EUR 107.69M

Net Cash

EUR 20.38M

Net Cash Per Share

EUR 0.40

Tangible Book Value Per Share

EUR 13.32

Gross margin is 64.02%, with operating margin of 21.97%, and net profit margin of 23.95%.

Gross Margin

64.02%

Operating Margin

21.97%

Pretax Margin

30.43%

Net Profit Margin

23.95%

EBITDA Margin

34.43%

EBIT Margin

30.08%

The average price target for Laboratorios Farmaceuticos Rovi is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

3.21%

EPS Growth Forecast

39.34%

Smart Score

4

AI Score

―